PMID- 29740535
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220321
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 8
DP  - 2018
TI  - Enhancing the Therapeutic Efficacy of Cancer Treatment With Cannabinoids.
PG  - 114
LID - 10.3389/fonc.2018.00114 [doi]
LID - 114
AB  - Over the years, many in vitro and in vivo studies have shown the antineoplastic 
      effects of cannabinoids (CBDs), with reports advocating for investigations of 
      combination therapy approaches that could better leverage these effects in 
      clinical translation. This study explores the potential of combination approaches 
      employing CBDs with radiotherapy (RT) or smart biomaterials toward enhancing 
      therapeutic efficacy during treatment of pancreatic and lung cancers. In in vitro 
      studies, clonogenic assay results showed greater effective tumor cell killing, 
      when combining CBDs and RT. Meanwhile, in vivo study results revealed major 
      increase in survival when employing smart biomaterials for sustained delivery of 
      CBDs to tumor cells. The significance of these findings, considerations for 
      further research, and viable roadmap to clinical translation are discussed.
FAU - Yasmin-Karim, Sayeda
AU  - Yasmin-Karim S
AD  - Radiation Oncology, Brigham and Women's Hospital, Boston, MA, United States.
AD  - Dana-Farber Cancer Institute, Boston, MA, United States.
AD  - Harvard Medical School, Boston, MA, United States.
FAU - Moreau, Michele
AU  - Moreau M
AD  - Dana-Farber Cancer Institute, Boston, MA, United States.
AD  - Harvard Medical School, Boston, MA, United States.
AD  - University of Massachusetts Lowell, Lowell, MA, United States.
FAU - Mueller, Romy
AU  - Mueller R
AD  - Radiation Oncology, Brigham and Women's Hospital, Boston, MA, United States.
AD  - Dana-Farber Cancer Institute, Boston, MA, United States.
AD  - University Medical Center Mannheim, Heidelberg University, Mannheim, Germany.
FAU - Sinha, Neeharika
AU  - Sinha N
AD  - Radiation Oncology, Brigham and Women's Hospital, Boston, MA, United States.
AD  - Dana-Farber Cancer Institute, Boston, MA, United States.
FAU - Dabney, Raymond
AU  - Dabney R
AD  - Cannabis Science, Inc., Irvine, CA, United States.
FAU - Herman, Allen
AU  - Herman A
AD  - Cannabis Science, Inc., Irvine, CA, United States.
FAU - Ngwa, Wilfred
AU  - Ngwa W
AD  - Radiation Oncology, Brigham and Women's Hospital, Boston, MA, United States.
AD  - Dana-Farber Cancer Institute, Boston, MA, United States.
AD  - Harvard Medical School, Boston, MA, United States.
AD  - University of Massachusetts Lowell, Lowell, MA, United States.
LA  - eng
PT  - Journal Article
DEP - 20180424
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC5928848
OTO - NOTNLM
OT  - biomaterials
OT  - cancer
OT  - cannabinoids or endocannabinoids
OT  - radiotherapy
OT  - survival
EDAT- 2018/05/10 06:00
MHDA- 2018/05/10 06:01
PMCR- 2018/01/01
CRDT- 2018/05/10 06:00
PHST- 2018/01/16 00:00 [received]
PHST- 2018/03/29 00:00 [accepted]
PHST- 2018/05/10 06:00 [entrez]
PHST- 2018/05/10 06:00 [pubmed]
PHST- 2018/05/10 06:01 [medline]
PHST- 2018/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2018.00114 [doi]
PST - epublish
SO  - Front Oncol. 2018 Apr 24;8:114. doi: 10.3389/fonc.2018.00114. eCollection 2018.